NCT03366779Unknown4 期
A Post Marketing Surveillance Study To Monitor The Early Safety And Performance Of The BARRICAID® Anular Closure Device In The Treatment Of Radicular Pain Caused By Primary Lumbar Disc Herniation
Intrinsic Therapeutics4 个研究点 分布在 2 个国家目标入组 20 人开始时间: 2018年1月16日最近更新:
适应症
干预措施
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Device stability
研究概览
简要总结
This study is a prospective, multi-center study to monitor the early safety and performance of one iteration of the Barricaid Anular Closure Device (ACD) - 6mm anchor width, when used as an adjunct to limited discectomy.
详细描述
This study is planned to collect information on use of the Barricaid ACD with an anchor width of 6mm. Other iterations of the device are made with an 8mm wide anchor. The narrower anchor was designed to optimize surgeon visualization during implantation, and has undergone all appropriate rigorous testing prior to release. Safety will be evaluated to demonstrate acceptable levels of device-related and procedure-related complications. This limited market release will allow its performance to be evaluated by examining the effects on reoperation, device deficiencies, patient pain scores and disability after discectomy with ACD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 75 years old (male or female).
- •Patients with posterior or posterolateral disc herniations at one level between L1 and S1 with radiographic confirmation of neural compression using CT and/or MRI.
- •At least six (6) weeks of failed, conservative treatment prior to surgery, or requires immediate surgery to prevent permanent disability.
- •Minimum posterior disc height of 5mm at the index level(s).
- •Lower back pain and/or sciatica with or without spinal claudication.
- •Oswestry Questionnaire score of at least 40/100 at baseline.
- •VAS leg pain of at least 40/100 at baseline.
- •Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.
排除标准
- •Spondylolisthesis Grade II or higher.
- •Subject requires uni or bilateral facetectomy to treat leg/back pain.
- •Subject has back or non-radicular leg pain of unknown etiology.
- •Prior surgery at the index lumbar level.
- •Subject requiring a spine DEXA (i.e., patients with SCORE of ≥ 6) with a T Score less than -2.0 at the index level. For patients with a herniation at L5/S1, the average T score of L1-L4 shall be used.
- •Subject has clinically compromised vertebral bodies at the index level(s) due to any traumatic, neoplastic, metabolic, or infectious pathology.
- •Subject has sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip.
- •Subject has scoliosis of greater than ten (10) degrees (both angular and rotational).
- •Any metabolic disease bone disease that has not been stabilized for at least three months (e.g., Paget's disease, osteomalacia, osteogenesis imperfecta, thyroid and/or parathyroid gland disorder, etc.).
- •Subject has an active infection either systemic or local.
- •Subject has cauda equina syndrome or neurogenic bowel/bladder dysfunction.
- •Subject has severe arterial insufficiency of the legs (Screening on physical examination= patients with diminution or absence of dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is required with vascular plethysmography. If the absolute arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded) or other peripheral vascular disease).
- •Subject has significant peripheral neuropathy, patient defined as a patient with Type I or Type II diabetes or similar systemic metabolic condition causing decreased sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities.
- •Subject has insulin-dependent diabetes mellitus.
- •Subject is morbidly obese (defined as a body mass index >40, or weighs more than 100 lbs over ideal body weight).
- •Subject has been diagnosed with active hepatitis, AIDS, or HIV.
- •Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease.
- •Subject has a known allergy to titanium, polyethylene or polyester materials.
- •Subject is pregnant or interested in becoming pregnant in the next two (2) years.
- •Subject has active tuberculosis or has had tuberculosis in the past three (3) years.
- •Subject has a history of active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years.
- •Subject is immunologically suppressed, received steroids >1 month over the past year.
- •Currently taking anticoagulants, other than aspirin, unless the patient can be taken off the anticoagulant for surgery.
- •Subject has a current chemical/alcohol dependency or significant psychosocial disturbance.
- •Subject has a life expectancy of less than three (3) years.
- •Subject is currently involved in another investigational study.
- •Subject is incarcerated.
研究组 & 干预措施
Surgery with 6mm ACD
Other
ACD medical device (non-experimental). Surgical device implantation after standard lumbar discectomy.
干预措施: 6mm annular closure device (Device)
结局指标
主要结局
Device stability
时间窗: 3 months post implantation
To be considered a success the subjects would require to have a lack of implant migration through 3 months after surgery
次要结局
- Oswestry Disability Index(Through 24Month post implantation)
- Visual Analog scale - back pain(Through 24Month post implantation)
- Device condition, reoperation at index level and long term performance(Through 24Month post implantation)
- Visual Analog Scale - leg pain(Through 24Month post implantation)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
4 期
Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean ChildrenHaemophilus Influenzae Type B InfectionNCT01404962Novartis Vaccines764
终止
不适用
A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckUnresectable Locally Advanced Squamous Cell Carcinoma of Head and NeckLA SCCHNNCT01303237Merck KGaA, Darmstadt, Germany88
已完成
不适用
Barricaid EU Post Market Study for Primary Lumbar Disc HerniationLumbar Disc HerniationNCT01534065Intrinsic Therapeutics45
终止
不适用
A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact CupArthritisFracture of the Femoral Neck or HeadCongenital Hip DysplasiaOsteoarthritisAvascular NecrosisNCT02196818Medacta International SA200
已完成
不适用
Prevenar13 Post Market SurveillanceHealthyNCT01509105Pfizer649